Senseonics brings one-year Eversense 365 CGM to Beta Bionics iLet platform
Senseonics and Beta Bionics plan to integrate Eversense 365 with iLet, pairing one-year implantable CGM with automated insulin delivery.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
FDA authorizes Abbott Libre Duo as first continuous glucose-ketone wearable
Libre Duo 10 Day continuously measures glucose and ketones every minute for people with diabetes aged two and older, creating the first US integrated glucose-ketone monitoring category.
Features & Analysis
Should people without diabetes wear continuous glucose monitors? What the evidence actually shows
FDA-cleared OTC glucose sensors have opened continuous monitoring to people who do not use insulin, but evidence for weight loss and broad metabolic improvement in people without diabetes remains limited.
Medical Devices & Diagnostics
Why MultiDimension Technology’s tiny 50 nA chip could matter before a CGM is ever worn
MultiDimension Technology’s TMR1370 targets two-year CGM standby with 50 nA current, but device-level validation will decide its impact.
Medical Devices & Diagnostics
Can Dexcom G7 reshape CGM adoption for type 2 diabetes patients not using insulin?
Find out how Dexcom G7 data could reshape CGM adoption for type 2 diabetes patients not using insulin.
Medical Devices & Diagnostics
Why Glucotrack’s CBGM filing could test the next frontier in diabetes monitoring
Wearable CGMs dominate diabetes care. Glucotrack’s implantable CBGM now faces the harder FDA test: durable blood-based proof.
Medical Devices & Diagnostics
Why Sequenex’s MedTech Innovator partnership matters for connected device startups
Medtech startups have sensors, but software can slow them down. Sequenex’s MedTech Innovator tie up targets that commercialization gap.
Pharma & Biotech
Rezolute’s ersodetug data deepens the congenital hyperinsulinism regulatory debate
Rezolute, Inc. has presented expanded Phase 3 sunRIZE data for ersodetug in congenital hyperinsulinism at the Pediatric Endocrine Society Annual Meeting, adding continuous glucose monitoring outcomes and open-label extension observations to a program that previously missed its primary endpoint. The update places the late-stage rare disease biotech firm in a complex regulatory position, as the
Medical Devices & Diagnostics
Can Medtronic and Abbott redefine insulin delivery with the Instinct-integrated MiniMed 780G?
Medtronic’s MiniMed 780G now ships in the U.S. with Abbott’s Instinct sensor. Explore how this launch could reshape CGM-insulin system competition.